Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by MicrocapManiacon May 16, 2013 10:10am

79 Views

Post# 21402626

RE: Absorica 9.4% as of Apr 29, 2013

With a 9.4% market share for Absorica and roughly $0.06 annual contibution from their other drugs we get about $0.36 eps in 12 months. Thus at current prices it's trading at about 10 times earnings at current run rates. It's really amazing how cheap this pharma company is trading.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity